Goodwin Advises Myricx Bio on Acquisition by Novartis to Advance Next-Generation ADC Payloads for Oncology
July 06, 2026
July 06, 2026
BOSTON, Massachusetts, July 6 [Category: BizLaw/Legal] -- Goodwin, a law firm, posted the following news release:
* * *
Goodwin Advises Myricx Bio on Acquisition by Novartis to Advance Next-Generation ADC Payloads for Oncology
*
The Life Sciences team advised Myricx Bio on its agreement to be acquired by Novartis for up to $1.5 billion, including $1.1 billion in upfront cash plus potential milestone payments. The acquisition brings together Nov . . .
* * *
Goodwin Advises Myricx Bio on Acquisition by Novartis to Advance Next-Generation ADC Payloads for Oncology
*
The Life Sciences team advised Myricx Bio on its agreement to be acquired by Novartis for up to $1.5 billion, including $1.1 billion in upfront cash plus potential milestone payments. The acquisition brings together Nov . . .